HESI Mental Health Practice
Test – HESI NGN 2026/2027 –
Comprehensive Study Guide
PART 0: THE NAVIGATOR
Section Focus Question Range Cognitive Framework 2026 Clinical Domain
Integration
Foundational Syntax & Q1 – Q15 Recall, Recognition, & 2026 Pharmacopeia
Application Basic Application (Cobenfy, Exxua),
DSM-5-TR, CMS F605
Legal Standards,
Ambient AI Ethics.
Professional Simulation Q16 – Q40 Analysis & Immediate Acute Crisis
Intervention De-escalation,
Toxicological Antidotes,
Milieu Management,
Neurological
Emergencies.
Grandmaster Synthesis Q41 – Q55 Synthesis, Evaluation, NGN Clinical Judgment
(NGN) & High-Stakes Triage Measurement Model
(NCJMM),
Multi-System Failure,
Mass Casualty Triage.
PART I: THE PRIMER
Mastering psychiatric-mental health nursing mechanics distinguishes the novice from the elite
clinical decision-maker in the 2026 healthcare landscape. Precision in advanced
psychopharmacology, legal thresholds, and neurobiological assessment directly dictates patient
survival, organizational compliance, and licensure success.
● Lithium Toxicity: Levels >1.5 mEq/L constitute toxicity; prioritize aggressive intravenous
hydration and hemodialysis immediately.
● Cobenfy Protocol: M1/M4 muscarinic agonist; strictly contraindicated in narrow-angle
glaucoma, urinary retention, and hepatic impairment.
● Exxua Protocol: 5-HT1A agonist; strictly contraindicated with a baseline QTc > 450 msec
or within 14 days of an MAOI.
● CMS F605: Psychotropic PRN orders are capped at 14 days; use for staff convenience is
an illegal chemical restraint.
● Ambient AI Liability: Clinicians retain absolute legal liability for AI-generated clinical
documentation; mandatory human review is non-negotiable.
,PART II: THE ELITE TEST BANK
Q1: The 2024/2025 FDA approval of Cobenfy (xanomeline and trospium chloride)
introduced a revolutionary mechanism for treating schizophrenia. The clinician
recognizes that this medication achieves antipsychotic efficacy without inducing the
extrapyramidal symptoms (EPS) typical of first-generation antipsychotics by targeting
which of the following systems? A) Selective 5-HT1A presynaptic autoreceptors B) M1 and
M4 muscarinic cholinergic receptors C) GABA-A receptor chloride ion channels D) Dopamine
D2 and serotonin 5-HT2A receptors
● The Answer: B (M1 and M4 muscarinic cholinergic receptors)
● Distractor Analysis: Option A describes Exxua (gepirone). Option C describes
benzodiazepines. Option D describes standard second-generation atypical antipsychotics
(SGAs). None of these address the novel mechanism of Cobenfy.
● The Mentor's Analysis: Cobenfy represents a paradigm shift in the 2026 pharmacopeia.
By selectively agonizing M1 and M4 muscarinic receptors centrally (xanomeline) while
blocking peripheral muscarinic receptors (trospium) to mitigate severe systemic side
effects, it treats psychosis without the dopamine D2 receptor blockade that inherently
causes EPS and tardive dyskinesia.
Q2: A patient is prescribed Exxua (gepirone) for Major Depressive Disorder (MDD). Prior
to initiating the first dose, the professional must obtain a baseline electrocardiogram
(ECG) to definitively rule out which of the following absolute contraindications? A) QTc
interval greater than 450 msec B) Heart rate less than 60 beats per minute C) PR interval
greater than 200 msec D) Ejection fraction of 55%
● The Answer: A (QTc interval greater than 450 msec)
● Distractor Analysis: While bradycardia (B) and first-degree heart block (C) require
routine monitoring, the specific black-box warning and absolute contraindication for
gepirone initiation is a prolonged QTc interval due to the risk of fatal arrhythmias.
● The Mentor's Analysis: Exxua carries a significant proarrhythmic risk profile.
Professional intuition dictates that any medication carrying a QTc prolongation warning
mandates baseline and continuous ECG monitoring. A QTc > 450 msec is the hard-deck
cutoff for initiating this therapy, requiring the clinician to hold the dose and immediately
notify the prescriber.
Q3: Under the updated 2025/2026 FDA Risk Evaluation and Mitigation Strategy (REMS)
guidelines for clozapine, which of the following statements represents the current
standard of practice for dispensing this atypical antipsychotic? A) Absolute neutrophil
count (ANC) reporting to the REMS database is mandatory before a pharmacy can dispense the
drug. B) The REMS program has been entirely eliminated, and ANC monitoring is no longer
clinically required for any patient. C) Pharmacies may dispense clozapine without REMS
reporting, but the clinician is still clinically mandated to monitor ANC per the Boxed Warning. D)
Clozapine can now be prescribed without routine laboratory work if the patient exhibits no
subjective signs of systemic infection.
● The Answer: C (Pharmacies may dispense clozapine without REMS reporting, but the
clinician is still clinically mandated to monitor ANC per the Boxed Warning.)
● Distractor Analysis: Option A is the outdated pre-2025 standard. Options B and D are
highly dangerous; the biological risk of severe neutropenia remains unchanged, making
clinical monitoring essential regardless of administrative requirements.
, ● The Mentor's Analysis: The FDA eliminated the administrative burden of the REMS
reporting system to improve patient access, but the physiological threat of fatal
agranulocytosis remains a biological reality. Elite clinicians clearly separate administrative
red tape from physiological mandates; the ANC must still be monitored rigorously.
Q4: A surveyor reviewing a long-term care facility's compliance with CMS F605 identifies
a PRN order for haloperidol. To avoid an Immediate Jeopardy citation for chemical
restraint, the PRN order must strictly expire within what timeframe unless a specific,
newly documented rationale is provided by the prescriber? A) 48 hours B) 7 days C) 14
days D) 30 days
● The Answer: C (14 days)
● Distractor Analysis: Options A, B, and D are incorrect regulatory timeframes. 14 days is
the explicit CMS federal threshold for PRN psychotropics.
● The Mentor's Analysis: CMS F605 dictates that psychotropic medications cannot be
used for staff convenience or generic discipline. A PRN psychotropic order is federally
capped at 14 days to force the interdisciplinary team to re-evaluate the medical necessity
of the intervention. Extending it requires exhaustive documentation of the continuing
psychiatric emergency.
Q5: A clinician is utilizing an Ambient AI documentation tool during a complex
psychiatric intake. The AI generates a transcript and a formulated SOAP note. According
to 2026 medico-legal standards, who holds the ultimate liability for any "hallucinated" or
erroneous clinical data in the finalized, signed chart? A) The healthcare facility's IT
infrastructure department B) The third-party vendor providing the Ambient AI software C) The
signing clinician D) The clinical nursing supervisor who countersigns all unit admissions
● The Answer: C (The signing clinician)
● Distractor Analysis: Blaming the software (B) or IT (A) does not hold up in malpractice
law. The supervisor (D) is not directly observing or charting the encounter.
● The Mentor's Analysis: Ambient AI is a copilot, not a replacement for clinical judgment
or legal accountability. If a clinician blindly signs an electronic document containing an AI
hallucination, they have legally adopted that error as their own clinical assessment.
Human-in-the-loop review is a non-negotiable legal standard in the digital therapeutics
era.
Q6: A patient taking a second-generation antipsychotic (SGA) is undergoing routine
metabolic syndrome monitoring. Which cluster of physiological parameters accurately
reflects the diagnostic criteria for metabolic syndrome that the professional must
identify? A) Elevated AST/ALT, resting bradycardia, and unintentional weight loss B) Elevated
blood pressure, elevated triglycerides, and increased abdominal circumference C) Profound
hypoglycemia, orthostatic hypotension, and elevated high-density lipoprotein (HDL) D)
Hypercalcemia, hypokalemia, and elevated thyroid-stimulating hormone (TSH)
● The Answer: B (Elevated blood pressure, elevated triglycerides, and increased
abdominal circumference)
● Distractor Analysis: SGAs cause massive weight gain, not loss (A). They induce
hyperglycemia and lower HDL, not hypoglycemia/elevated HDL (C). Option D lists
unrelated endocrine and electrolyte imbalances.
● The Mentor's Analysis: SGAs violently disrupt glucose and lipid metabolism while
blocking histamine receptors (driving extreme appetite). Monitoring waist circumference,
fasting glucose, triglycerides, and blood pressure is the gold standard for preventing
secondary cardiovascular mortality in psychiatric populations.
Q7: During an admission assessment for a patient presenting with acute confusion, the
Test – HESI NGN 2026/2027 –
Comprehensive Study Guide
PART 0: THE NAVIGATOR
Section Focus Question Range Cognitive Framework 2026 Clinical Domain
Integration
Foundational Syntax & Q1 – Q15 Recall, Recognition, & 2026 Pharmacopeia
Application Basic Application (Cobenfy, Exxua),
DSM-5-TR, CMS F605
Legal Standards,
Ambient AI Ethics.
Professional Simulation Q16 – Q40 Analysis & Immediate Acute Crisis
Intervention De-escalation,
Toxicological Antidotes,
Milieu Management,
Neurological
Emergencies.
Grandmaster Synthesis Q41 – Q55 Synthesis, Evaluation, NGN Clinical Judgment
(NGN) & High-Stakes Triage Measurement Model
(NCJMM),
Multi-System Failure,
Mass Casualty Triage.
PART I: THE PRIMER
Mastering psychiatric-mental health nursing mechanics distinguishes the novice from the elite
clinical decision-maker in the 2026 healthcare landscape. Precision in advanced
psychopharmacology, legal thresholds, and neurobiological assessment directly dictates patient
survival, organizational compliance, and licensure success.
● Lithium Toxicity: Levels >1.5 mEq/L constitute toxicity; prioritize aggressive intravenous
hydration and hemodialysis immediately.
● Cobenfy Protocol: M1/M4 muscarinic agonist; strictly contraindicated in narrow-angle
glaucoma, urinary retention, and hepatic impairment.
● Exxua Protocol: 5-HT1A agonist; strictly contraindicated with a baseline QTc > 450 msec
or within 14 days of an MAOI.
● CMS F605: Psychotropic PRN orders are capped at 14 days; use for staff convenience is
an illegal chemical restraint.
● Ambient AI Liability: Clinicians retain absolute legal liability for AI-generated clinical
documentation; mandatory human review is non-negotiable.
,PART II: THE ELITE TEST BANK
Q1: The 2024/2025 FDA approval of Cobenfy (xanomeline and trospium chloride)
introduced a revolutionary mechanism for treating schizophrenia. The clinician
recognizes that this medication achieves antipsychotic efficacy without inducing the
extrapyramidal symptoms (EPS) typical of first-generation antipsychotics by targeting
which of the following systems? A) Selective 5-HT1A presynaptic autoreceptors B) M1 and
M4 muscarinic cholinergic receptors C) GABA-A receptor chloride ion channels D) Dopamine
D2 and serotonin 5-HT2A receptors
● The Answer: B (M1 and M4 muscarinic cholinergic receptors)
● Distractor Analysis: Option A describes Exxua (gepirone). Option C describes
benzodiazepines. Option D describes standard second-generation atypical antipsychotics
(SGAs). None of these address the novel mechanism of Cobenfy.
● The Mentor's Analysis: Cobenfy represents a paradigm shift in the 2026 pharmacopeia.
By selectively agonizing M1 and M4 muscarinic receptors centrally (xanomeline) while
blocking peripheral muscarinic receptors (trospium) to mitigate severe systemic side
effects, it treats psychosis without the dopamine D2 receptor blockade that inherently
causes EPS and tardive dyskinesia.
Q2: A patient is prescribed Exxua (gepirone) for Major Depressive Disorder (MDD). Prior
to initiating the first dose, the professional must obtain a baseline electrocardiogram
(ECG) to definitively rule out which of the following absolute contraindications? A) QTc
interval greater than 450 msec B) Heart rate less than 60 beats per minute C) PR interval
greater than 200 msec D) Ejection fraction of 55%
● The Answer: A (QTc interval greater than 450 msec)
● Distractor Analysis: While bradycardia (B) and first-degree heart block (C) require
routine monitoring, the specific black-box warning and absolute contraindication for
gepirone initiation is a prolonged QTc interval due to the risk of fatal arrhythmias.
● The Mentor's Analysis: Exxua carries a significant proarrhythmic risk profile.
Professional intuition dictates that any medication carrying a QTc prolongation warning
mandates baseline and continuous ECG monitoring. A QTc > 450 msec is the hard-deck
cutoff for initiating this therapy, requiring the clinician to hold the dose and immediately
notify the prescriber.
Q3: Under the updated 2025/2026 FDA Risk Evaluation and Mitigation Strategy (REMS)
guidelines for clozapine, which of the following statements represents the current
standard of practice for dispensing this atypical antipsychotic? A) Absolute neutrophil
count (ANC) reporting to the REMS database is mandatory before a pharmacy can dispense the
drug. B) The REMS program has been entirely eliminated, and ANC monitoring is no longer
clinically required for any patient. C) Pharmacies may dispense clozapine without REMS
reporting, but the clinician is still clinically mandated to monitor ANC per the Boxed Warning. D)
Clozapine can now be prescribed without routine laboratory work if the patient exhibits no
subjective signs of systemic infection.
● The Answer: C (Pharmacies may dispense clozapine without REMS reporting, but the
clinician is still clinically mandated to monitor ANC per the Boxed Warning.)
● Distractor Analysis: Option A is the outdated pre-2025 standard. Options B and D are
highly dangerous; the biological risk of severe neutropenia remains unchanged, making
clinical monitoring essential regardless of administrative requirements.
, ● The Mentor's Analysis: The FDA eliminated the administrative burden of the REMS
reporting system to improve patient access, but the physiological threat of fatal
agranulocytosis remains a biological reality. Elite clinicians clearly separate administrative
red tape from physiological mandates; the ANC must still be monitored rigorously.
Q4: A surveyor reviewing a long-term care facility's compliance with CMS F605 identifies
a PRN order for haloperidol. To avoid an Immediate Jeopardy citation for chemical
restraint, the PRN order must strictly expire within what timeframe unless a specific,
newly documented rationale is provided by the prescriber? A) 48 hours B) 7 days C) 14
days D) 30 days
● The Answer: C (14 days)
● Distractor Analysis: Options A, B, and D are incorrect regulatory timeframes. 14 days is
the explicit CMS federal threshold for PRN psychotropics.
● The Mentor's Analysis: CMS F605 dictates that psychotropic medications cannot be
used for staff convenience or generic discipline. A PRN psychotropic order is federally
capped at 14 days to force the interdisciplinary team to re-evaluate the medical necessity
of the intervention. Extending it requires exhaustive documentation of the continuing
psychiatric emergency.
Q5: A clinician is utilizing an Ambient AI documentation tool during a complex
psychiatric intake. The AI generates a transcript and a formulated SOAP note. According
to 2026 medico-legal standards, who holds the ultimate liability for any "hallucinated" or
erroneous clinical data in the finalized, signed chart? A) The healthcare facility's IT
infrastructure department B) The third-party vendor providing the Ambient AI software C) The
signing clinician D) The clinical nursing supervisor who countersigns all unit admissions
● The Answer: C (The signing clinician)
● Distractor Analysis: Blaming the software (B) or IT (A) does not hold up in malpractice
law. The supervisor (D) is not directly observing or charting the encounter.
● The Mentor's Analysis: Ambient AI is a copilot, not a replacement for clinical judgment
or legal accountability. If a clinician blindly signs an electronic document containing an AI
hallucination, they have legally adopted that error as their own clinical assessment.
Human-in-the-loop review is a non-negotiable legal standard in the digital therapeutics
era.
Q6: A patient taking a second-generation antipsychotic (SGA) is undergoing routine
metabolic syndrome monitoring. Which cluster of physiological parameters accurately
reflects the diagnostic criteria for metabolic syndrome that the professional must
identify? A) Elevated AST/ALT, resting bradycardia, and unintentional weight loss B) Elevated
blood pressure, elevated triglycerides, and increased abdominal circumference C) Profound
hypoglycemia, orthostatic hypotension, and elevated high-density lipoprotein (HDL) D)
Hypercalcemia, hypokalemia, and elevated thyroid-stimulating hormone (TSH)
● The Answer: B (Elevated blood pressure, elevated triglycerides, and increased
abdominal circumference)
● Distractor Analysis: SGAs cause massive weight gain, not loss (A). They induce
hyperglycemia and lower HDL, not hypoglycemia/elevated HDL (C). Option D lists
unrelated endocrine and electrolyte imbalances.
● The Mentor's Analysis: SGAs violently disrupt glucose and lipid metabolism while
blocking histamine receptors (driving extreme appetite). Monitoring waist circumference,
fasting glucose, triglycerides, and blood pressure is the gold standard for preventing
secondary cardiovascular mortality in psychiatric populations.
Q7: During an admission assessment for a patient presenting with acute confusion, the
